Basel: Sale and leaseback for Basilea headquarters
Basilea Pharmaceutica has sold its headquarters at Grenzacherstrasse in Basel to the UBS pension fund via a sale and leaseback transaction.
Basilea Pharmaceutica announced that the gross proceeds from the sale - before fees and transaction costs - amount to approximately CHF 19 million. The building will be leased back and no further organizational changes are planned in connection with this transaction. CBRE advised Basilea on the sale of the property at Grenzacherstrasse 487.
According to CEO David Veitch, the transaction increases the company's financial and operational flexibility. In the medium term, it intends to bring together all employees currently working at different locations in Basel at a new site in the region.
Basilea Pharmaceutica was spun off from F. Hoffmann-La Roche in 2000 and has been listed on the Swiss stock exchange since March 2004. The company develops drugs for the treatment of bacterial infections and fungal diseases. (ah)
